SH3GL1 and breast cancer: Although patient outcomes were not available for the cohort previously mentioned, we tested whether differential expression of Endo II gene Sh3gl1 had any significant associations with outcomes in patients with node-positive HER2+ breast cancer using open-access Kaplan–Meier Plotter microarray data [26].